Late-stage ulcerative colitis pipeline continues to innovate
Pharmaceutical Technology
JULY 28, 2022
This is an important population to target, as it is well-documented that a number of patients are intolerant or non-responsive to first-line biologics like infliximab or adalimumab. GlobalData expects regulatory approval of mirikizumab for UC in the US and European Union (EU) next year.
Let's personalize your content